ATE412183T1 - Brca1-marker - Google Patents

Brca1-marker

Info

Publication number
ATE412183T1
ATE412183T1 AT05754413T AT05754413T ATE412183T1 AT E412183 T1 ATE412183 T1 AT E412183T1 AT 05754413 T AT05754413 T AT 05754413T AT 05754413 T AT05754413 T AT 05754413T AT E412183 T1 ATE412183 T1 AT E412183T1
Authority
AT
Austria
Prior art keywords
brca1
assaying
expression
family
specific member
Prior art date
Application number
AT05754413T
Other languages
English (en)
Inventor
Paul Harkin
Original Assignee
Univ Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Belfast filed Critical Univ Belfast
Application granted granted Critical
Publication of ATE412183T1 publication Critical patent/ATE412183T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • Road Signs Or Road Markings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
AT05754413T 2004-06-05 2005-06-06 Brca1-marker ATE412183T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0412620.7A GB0412620D0 (en) 2004-06-05 2004-06-05 BRCA1 markers

Publications (1)

Publication Number Publication Date
ATE412183T1 true ATE412183T1 (de) 2008-11-15

Family

ID=32696748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05754413T ATE412183T1 (de) 2004-06-05 2005-06-06 Brca1-marker

Country Status (6)

Country Link
US (1) US20080268435A1 (de)
EP (1) EP1754061B1 (de)
AT (1) ATE412183T1 (de)
DE (1) DE602005010575D1 (de)
GB (1) GB0412620D0 (de)
WO (1) WO2005121786A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5461201B2 (ja) * 2008-01-31 2014-04-02 学校法人慶應義塾 抗がん剤感受性の判定方法
WO2013130869A1 (en) * 2012-02-28 2013-09-06 Siemens Healthcare Diagnostics, Inc. Gene expression signatures in cancer
WO2013148370A1 (en) * 2012-03-30 2013-10-03 Sloan-Kettering Institute For Cancer Research S100a8/a9 as a diagnostic marker and a therapeutic target
WO2016185406A1 (en) * 2015-05-19 2016-11-24 Nadathur Estates Pvt. Ltd. Method for identification of a deficient brca1 function
US11413288B2 (en) 2017-11-01 2022-08-16 Dana-Farber Cancer Institute, Inc. Methods of treating cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026668A2 (en) * 1998-11-05 2000-05-11 The Regents Of The University Of Michigan S100 proteins and autoantibodies as serum markers for cancer
AU2002367317A1 (en) * 2001-12-31 2003-07-24 Dana-Farber Cancer Institute, Inc. Psoriasin expression by breast epithelial cells
AU2003201741A1 (en) * 2002-01-09 2003-07-24 Yusuke Nakamura Cancer profiles

Also Published As

Publication number Publication date
US20080268435A1 (en) 2008-10-30
EP1754061A2 (de) 2007-02-21
GB0412620D0 (en) 2004-07-07
WO2005121786A2 (en) 2005-12-22
WO2005121786A3 (en) 2006-04-27
DE602005010575D1 (en) 2008-12-04
EP1754061B1 (de) 2008-10-22

Similar Documents

Publication Publication Date Title
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
Pan et al. m5C-related lncRNAs predict overall survival of patients and regulate the tumor immune microenvironment in lung adenocarcinoma
WO2008030845A8 (en) Methods of predicting distant metastasis of lymph node-negative primary breast cancer using biological pathway gene expression analysis
Shima et al. N 1-methyladenosine (m1A) RNA modification: the key to ribosome control
WO2008060651A8 (en) Sparc and methods of use thereof
WO2007082099A3 (en) Gene expression markers for colorectal cancer prognosis
JP2008501336A5 (de)
WO2005100606A3 (en) Gene expression markers for predicting response to chemotherapy
US20160312294A1 (en) Prostate cancer classification
WO2005068664A3 (en) Cell-type-specific patterns of gene expression
NZ591711A (en) A method for predicting athletic performance potential
CA2642542A1 (en) Reagents and methods for cancer prognosis and pathological staging
EP2021534A4 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
ATE457362T1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
ATE414180T1 (de) Verwendung der gene kir2.3 und drd2 als molekulare marker zur diagnose von schizophrenie
WO2005003387A3 (en) Specific method of prostate cancer detection based on pca3 gene, and kits therefor
RU2011134644A (ru) Способы определения восприимчивости пациента к внутрибольничной инфекции и составления прогноза развития септического синдрома
ATE412183T1 (de) Brca1-marker
WO2019204340A3 (en) Biomarker for predicting equine gait and methods of use thereof
FR2855832B1 (fr) Procede de diagnostic et/ou de pronostic d'un syndrome septique
WO2005118875A3 (en) Diagnosing or predicting the course of breast cancer
BRPI0614445B8 (pt) ensaio de ácido nucleico para resistência de fármaco de equinocandina em fungos suscetíveis aos fármacos de equinocandina e contendo o gene fks1 que corresponde a subunidade fks1p 1,3-?-d-glicano sintase, bem como conjunto de oligonucleotídeos e kit de reagentes de amplificação
WO2005015236A3 (en) A method for predicting the progression of adenocarcinoma
Abdrabou et al. nuPRISM: Microfluidic genome-wide phenotypic screening platform for cellular nuclei
WO2008119027A3 (en) Genetic testing of telomere-associated genes in dyskeratosis congenita and related disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties